Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 3/2019

16.04.2019 | HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection

verfasst von: Emily Bowman, Nicholas T. Funderburg

Erschienen in: Current HIV/AIDS Reports | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Human immunodeficiency virus (HIV) infection and its treatment with antiretroviral therapy (ART) are associated with lipid abnormalities that may enhance cardiovascular disease risk (CVD).

Recent Findings

Chronic inflammation persists in HIV+ individuals, and complex relationships exist among lipids and inflammation, as immune activation may be both a cause and a consequence of lipid abnormalities in HIV infection. Advances in mass spectrometry-based techniques now allow for detailed measurements of individual lipid species; improved lipid measurement might better evaluate CVD risk compared with the prognostic value of traditional assessments.

Summary

Lipidomic analyses have begun to characterize dynamic changes in lipid composition during HIV infection and following treatment with ART, and further investigation may identify novel lipid biomarkers predictive of adverse outcomes. Developing strategies to improve management of comorbidities in the HIV+ population is important, and statin therapy and lifestyle modifications, including diet and exercise, may help to improve lipid levels and mitigate CVD risk.
Literatur
1.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12.CrossRefPubMed
2.
• Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138(11):1100–12. This work provides a thorough description of CVD burden in the global HIV+ population, and discusses the importance of improving strategies for risk stratification and treatment. CrossRefPubMedPubMedCentral
3.
Grunfeld CPM, Doerrler W, Shigenaga J, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045–52.PubMed
4.
Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis. 2013;13(11):964–75.CrossRefPubMed
5.
6.
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48–62.CrossRefPubMed
7.
Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199(1):79–86.CrossRefPubMed
8.
Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. Nat Rev Mol Cell Biol. 2018;19(5):281–96.CrossRefPubMed
9.
10.
Cassol EMV, Holman A, Kamat A, Morgello S, Gabuzda D. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis. 2013;13:203–20.CrossRefPubMedPubMedCentral
11.
Hodge AMED, O'Dea K, Sinclair AJ, Makrides M, Gibson RA, Giles GG. Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: interpreting the role of linoleic acid. Am J Clin Nutr. 2007;86:189–97.CrossRefPubMed
12.
Suvitaival T, Bondia-Pons I, Yetukuri L, Poho P, Nolan JJ, Hyotylainen T, et al. Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men. Metabolism. 2018;78:1–12.CrossRefPubMed
13.
Tavares De Almeida I, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002;21(3):219–23.CrossRefPubMed
14.
Akerele OA, Cheema SK. Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis. Med Hypotheses. 2015;85(6):754–60.CrossRefPubMed
15.
Stamler JDM, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 2000;284(3):311–8.CrossRefPubMed
16.
Willig AL, Overton ET. Metabolic consequences of HIV: pathogenic insights. Curr HIV/AIDS Rep. 2014;11(1):35–44.CrossRefPubMed
17.
Estrada VPJ. Dyslipidemia related to antiretroviral therapy. AIDS Rev. 2011;13:49–56.PubMed
18.
Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25(2):185–95.CrossRefPubMed
19.
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.CrossRefPubMed
20.
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.CrossRefPubMed
21.
AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.CrossRef
22.
23.
Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol. 2006;26(5):1144–9.CrossRefPubMed
24.
Triolo M, Annema W, Dullaart RPF, Tietge UJF. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark Med. 2013;7(3):457–72.CrossRefPubMed
25.
Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;181(Supplement_3):S462–S72.CrossRefPubMed
26.
Qiu C, Zhao X, Zhou Q, Zhang Z. High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis. Lipids Health Dis. 2017;16(1):212.CrossRefPubMedPubMedCentral
27.
Dullaart RP, Annema W, Tio RA, Tietge UJ. The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol. Clin Chim Acta. 2014;433:34–8.CrossRefPubMed
28.
29.
McGillicuddy FC, de la Llera MM, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119(8):1135–45.CrossRefPubMedPubMedCentral
30.
31.
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71.CrossRefPubMed
32.
Maisa A, Hearps AC, Angelovich TA, Pereira CF, Zhou J, Shi MD, et al. Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration. AIDS. 2015;29(12):1445–57.CrossRefPubMed
33.
Feeney ER, McAuley N, O'Halloran JA, Rock C, Low J, Satchell CS, et al. The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. J Infect Dis. 2013;207(4):628–37.CrossRefPubMed
34.
Asztalos BF, Mujawar Z, Morrow MP, Grant A, Pushkarsky T, Wanke C, et al. Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux. J Infect Dis. 2010;202(4):614–23.CrossRefPubMed
35.
Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4(11):e365.CrossRefPubMedPubMedCentral
36.
Sammalkorpi K, Valtonen V, Kerttula Y, Nikkilä E, Taskinen M-R. Changes in serum lipoprotein pattern induced by acute infections. Metab Clin Exp. 1988;37(9):859–65.CrossRefPubMed
37.
Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum. 2007;56(2):631–8.CrossRefPubMed
38.
Mostaza JM, Camino N, Gerique JG, Peña R, Baquero M, Lahoz C. C-reactive protein levels and prevalence of chronic infections in subjects with hypoalphalipoproteinemia. Metabolism. 2005;54(1):33–7.CrossRefPubMed
39.
Friis-Moller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-HIV drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23(2):214–23.CrossRefPubMed
40.
Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis. 2009;207(2):524–9.CrossRefPubMedPubMedCentral
41.
Bucher HC, Richter W, Glass TR, Magenta L, Wang Q, Cavassini M, et al. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2012;60(2):135–42.CrossRefPubMed
42.
Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119(7):931–9.CrossRefPubMedPubMedCentral
43.
Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007;7(1):53–72.CrossRefPubMed
44.
St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25(3):553–9.CrossRefPubMed
45.
Munger AM, Chow DC, Playford MP, Parikh NI, Gangcuangco LM, Nakamoto BK, et al. Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retrovir. 2015;31(2):221–8.CrossRefPubMedPubMedCentral
46.
Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, et al. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013;208(6):884–91.CrossRefPubMedPubMedCentral
47.
• Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, et al. Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antivir Ther. 2017;22(1):71–5. This study examines longitudinal changes in lipid composition and function in HIV+ individuals initiating a raltegravir-based ART regimen. These analyses may better assess CVD risk than traditional lipid measurements.CrossRefPubMed
48.
McCausland MR, Juchnowski SM, Zidar DA, Kuritzkes DR, Andrade A, Sieg SF, et al. Altered monocyte phenotype in HIV-1 infection tends to normalize with integrase-inhibitor-based antiretroviral therapy. PLoS One. 2015;10(10):e0139474.CrossRefPubMedPubMedCentral
49.
Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, Clagett B, et al. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One. 2013;8(12):e83514.CrossRefPubMedPubMedCentral
50.
Lo J, Rosenberg ES, Fitzgerald ML, Bazner SB, Ihenachor EJ, Hawxhurst V, et al. High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection. Open Forum Infect Dis. 2014;1(3):ofu108.CrossRefPubMedPubMedCentral
51.
Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51–83.CrossRefPubMedPubMedCentral
52.
GK H. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.CrossRef
53.
Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015;4(2).
54.
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.CrossRefPubMedPubMedCentral
55.
Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51(3):268–73.CrossRefPubMedPubMedCentral
56.
Wikby A, Nilsson BO, Forsey R, Thompson J, Strindhall J, Lofgren S, et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev. 2006;127(8):695–704.CrossRefPubMed
57.
Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506–12.CrossRefPubMed
58.
Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP, et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 2002;50(4):638–44.CrossRefPubMed
59.
Baker JV, Neuhaus J, Duprez D, Cooper DA, Hoy J, Kuller L, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS. 2011;25(17):2133–42.CrossRefPubMed
60.
Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M, et al. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS. 2013;27(3):381–9.CrossRefPubMed
61.
62.
Watson AD. Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006;47(10):2101–11.CrossRefPubMed
63.
Weir JM, Wong G, Barlow CK, Greeve MA, Kowalczyk A, Almasy L, et al. Plasma lipid profiling in a large population-based cohort. J Lipid Res. 2013;54(10):2898–908.CrossRefPubMedPubMedCentral
64.
Yang K, Cheng H, Gross RW, Han X. Automated lipid identification and quantification by multidimensional mass spectrometry-based shotgun lipidomics. Anal Chem. 2009;81(11):4356–68.CrossRefPubMedPubMedCentral
65.
Anand S, Young S, Esplin MS, Peaden B, Tolley HD, Porter TF, et al. Detection and confirmation of serum lipid biomarkers for preeclampsia using direct infusion mass spectrometry. J Lipid Res. 2016;57(4):687–96.CrossRefPubMedPubMedCentral
66.
Gorden DL, Myers DS, Ivanova PT, Fahy E, Maurya MR, Gupta S, et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res. 2015;56(3):722–36.CrossRefPubMedPubMedCentral
67.
Hu C, Zhou J, Yang S, Li H, Wang C, Fang X, et al. Oxidative stress leads to reduction of plasmalogen serving as a novel biomarker for systemic lupus erythematosus. Free Radic Biol Med. 2016;101:475–81.CrossRefPubMed
68.
Perrotti F, Rosa C, Cicalini I, Sacchetta P, Del Boccio P, Genovesi D, et al. Advances in lipidomics for cancer biomarkers discovery. Int J Mol Sci. 2016;17(12).
69.
Li J, Ren S, Piao HL, Wang F, Yin P, Xu C, et al. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer. Sci Rep. 2016;6:20984.CrossRefPubMedPubMedCentral
70.
Chen X, Chen H, Dai M, Ai J, Li Y, Mahon B, et al. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget. 2016;7(24):36622–31.PubMedPubMedCentral
71.
Fernandez C, Sandin M, Sampaio JL, Almgren P, Narkiewicz K, Hoffmann M, et al. Plasma lipid composition and risk of developing cardiovascular disease. PLoS One. 2013;8(8):e71846.CrossRefPubMedPubMedCentral
72.
Wong G, Trevillyan JM, Fatou B, Cinel M, Weir JM, Hoy JF, et al. Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction. PLoS One. 2014;9(4):e94810.CrossRefPubMedPubMedCentral
73.
Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014;129(18):1821–31.CrossRefPubMed
74.
Stegemann C, Drozdov I, Shalhoub J, Humphries J, Ladroue C, Didangelos A, et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circ Cardiovasc Genet. 2011;4(3):232–42.CrossRefPubMed
75.
Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121(4):1402–11.CrossRefPubMedPubMedCentral
76.
Harchaoui KEL, Visser ME, Kastelein JJP, Stroes ES, Dallinga-Thie GM. Triglycerides and cardiovascular risk. Curr Cardiol Rev. 2009;5(3):216–22.CrossRefPubMedPubMedCentral
77.
Haugaard SB, Andersen O, Pedersen SB, Dela F, Fenger M, Richelsen B, et al. Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism. 2006;55(2):175–82.CrossRefPubMed
78.
Moayyeri A, Hammond CJ, Valdes AM, Spector TD. Cohort Profile: TwinsUK and healthy ageing twin study. Int J Epidemiol. 2013;42(1):76–85.CrossRefPubMed
79.
Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvänne T, Hurme R, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014;99(1):E45–52.CrossRefPubMed
80.
Wu D, Ren Z, Pae M, Guo W, Cui X, Merrill AH, et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J Immunol. 2007;179(7):4829–39.CrossRefPubMed
81.
Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):1967–76.CrossRefPubMedPubMedCentral
82.
Yu J, Pan W, Shi R, Yang T, Li Y, Yu G, et al. Ceramide is upregulated and associated with mortality in patients with chronic heart failure. Can J Cardiol. 2015;31(3):357–63.CrossRefPubMed
83.
Peterson LR, Xanthakis V, Duncan MS, Gross S, Friedrich N, Volzke H, et al. Ceramide remodeling and risk of cardiovascular events and mortality. J Am Heart Assoc. 2018;7(10).
84.
Ueeda MDT, Takaya Y, Shinohata R, Katayma Y, Ohnishi N, Takaishi A, et al. Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J. 2008;72:1836–43.CrossRefPubMed
85.
Ellims AH, Wong G, Weir JM, Lew P, Meikle PJ, Taylor AJ. Plasma lipidomic analysis predicts non-calcified coronary artery plaque in asymptomatic patients at intermediate risk of coronary artery disease. Eur Heart J Cardiovasc Imaging. 2014;15(8):908–16.CrossRefPubMed
86.
Kulkarni MM, Ratcliff AN, Bhat M, Alwarawrah Y, Hughes P, Arcos J, et al. Cellular fatty acid synthase is required for late stages of HIV-1 replication. Retrovirology. 2017;14(1):45.CrossRefPubMedPubMedCentral
87.
• Belury MA, Bowman E, Gabriel J, Snyder B, Kulkarni M, Palettas M, et al. Prospective analysis of lipid composition changes with antiretroviral therapy and immune activation in persons living with HIV. Pathog Immun. 2017;2(3):376–403. This study examines longitudinal lipidome alterations in treatment-naïve HIV+ individuals at baseline, and after 48 weeks of a raltegravir-based ART regimen, and the relationships among pro-inflammatory lipid species and immune activation in this population. CrossRefPubMedPubMedCentral
88.
Funderburg NT. Prospective analysis of lipid compositional changes with antiretroviral therapy (ART) and immune activation in persons living with HIV. The 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; 2017 October 23–25; Milan, Italy.
89.
Wells IPG, Vincent JK. Lecithin: cholesterol acyltransferase and Lysolecithin in coronary atherosclerosis. Exp Mol Pathol. 1986;45:303–10.CrossRefPubMed
90.
Rabini RA, Galassi R, Fumelli P, Dousset N, Solera ML, Valdiguie P, et al. Reduced Na(+) -K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes. 1994;43(7):915–9.CrossRefPubMed
91.
Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM, et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2017;136(3):e1–e23.CrossRefPubMed
92.
Robblee MM, Kim CC, Porter Abate J, Valdearcos M, Sandlund KL, Shenoy MK, et al. Saturated fatty acids engage an IRE1alpha-dependent pathway to activate the NLRP3 inflammasome in myeloid cells. Cell Rep. 2016;14(11):2611–23.CrossRefPubMedPubMedCentral
93.
Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12(5):408–15.CrossRefPubMedPubMedCentral
94.
Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol. 2005;25(10):2062–8.CrossRefPubMed
95.
Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2007;27(1):84–91.CrossRefPubMed
96.
Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687–98.CrossRefPubMedPubMedCentral
97.
Yamada H, Yoshida M, Nakano Y, Suganami T, Satoh N, Mita T, et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2008;28(12):2173–9.CrossRefPubMed
98.
Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity. 2013;38(6):1154–63.CrossRefPubMed
99.
Kim SJ, Zhang Z, Saha A, Sarkar C, Zhao Z, Xu Y, et al. Omega-3 and omega-6 fatty acids suppress ER- and oxidative stress in cultured neurons and neuronal progenitor cells from mice lacking PPT1. Neurosci Lett. 2010;479(3):292–6.CrossRefPubMedPubMedCentral
100.
Pachikian BD, Essaghir A, Demoulin JB, Neyrinck AM, Catry E, De Backer FC, et al. Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets. PLoS One. 2011;6(8):e23365.CrossRefPubMedPubMedCentral
101.
Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454(7203):470–7.CrossRefPubMed
102.
Degirolamo C, Shelness GS, Rudel LL. LDL cholesteryl oleate as a predictor for atherosclerosis: evidence from human and animal studies on dietary fat. J Lipid Res. 2009;50(Suppl):S434–9.CrossRefPubMedPubMedCentral
103.
• Trevillyan JM, Wong G, Puls R, Petoumenos K, Emery S, Mellett NA, et al. Changes in plasma lipidome following initiation of antiretroviral therapy. PLoS One. 2018;13(8):e0202944. This study describes ART-induced changes to the HIV+ lipidome, and compares lipid alterations unique to 3 distinct ART regimens. CrossRefPubMedPubMedCentral
104.
Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, et al. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clin Trials. 2012;13(5):245–55.CrossRefPubMed
105.
Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis. 2015;61(3):445–52.CrossRefPubMedPubMedCentral
106.
107.
Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003;300(5622):1140–2.CrossRefPubMedPubMedCentral
108.
Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol. 2015;115(12):1760–6.CrossRefPubMed
109.
Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156–64.CrossRefPubMedPubMedCentral
110.
Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68(4):396–404.CrossRefPubMedPubMedCentral
111.
Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58(4):588–95.CrossRefPubMed
112.
Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59(8):1148–56.CrossRefPubMedPubMedCentral
113.
Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.CrossRefPubMedPubMedCentral
114.
Nou E, Lu MT, Looby SE, Fitch KV, Kim EA, Lee H, et al. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS. 2016;30(4):583–90.CrossRefPubMed
115.
Hileman CO, Turner R, Funderburg NT, Semba RD, McComsey GA. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS. 2016;30(1):65–73.PubMed
116.
Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22(10):1649–54.CrossRefPubMed
117.
Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014;28(14):2061–70.CrossRefPubMed
118.
Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top Antivir Med. 2016;23(4):146–9.
119.
Mitka M. Exploring statins to decrease hiv-related heart disease risk. JAMA. 2015;314(7):657–9.CrossRefPubMed
120.
Bergheanu SC, Reijmers T, Zwinderman AH, Bobeldijk I, Ramaker R, Liem A-H, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin. 2008;24(9):2477–87.CrossRefPubMed
121.
Central Committee for M, Community Program of the American Heart A. Dietary fat and its relation to heart attacks and strokes. JAMA. 1961;175(5):389–91.CrossRef
122.
Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7(3):e1000252.CrossRefPubMedPubMedCentral
123.
Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6):1505S–19S.CrossRefPubMed
124.
Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98(4A):27i–33i.CrossRefPubMed
125.
Appel LJ, Miller ER III, Seidler AJ, Whelton PK. Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med. 1993;153(12):1429–38.CrossRefPubMed
126.
Fedor D, Kelley DS. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care. 2009;12(2):138–46.CrossRefPubMed
127.
Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014;160(6):398–406.CrossRefPubMed
128.
Hileman CO, Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA. Omega-3 fatty acids do not improve endothelial function in virologically suppressed HIV-infected men: a randomized placebo-controlled trial. AIDS Res Hum Retrovir. 2012;28(7):649–55.CrossRefPubMed
Metadaten
Titel
Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection
verfasst von
Emily Bowman
Nicholas T. Funderburg
Publikationsdatum
16.04.2019
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 3/2019
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-019-00442-9

Weitere Artikel der Ausgabe 3/2019

Current HIV/AIDS Reports 3/2019 Zur Ausgabe

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Innate Lymphoid Cells: Their Contributions to Gastrointestinal Tissue Homeostasis and HIV/SIV Disease Pathology

Central Nervous System and Cognition (S Spudich, Section Editor)

Neurocognitive Phenotyping of HIV in the Era of Antiretroviral Therapy

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration

Correction

Correction to: Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?

Central Nervous System and Cognition (S Spudich, Section Editor)

Role of T Lymphocytes in HIV Neuropathogenesis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko

15.04.2024 | ACC 2024 | Kongressbericht | Nachrichten

Selbstexpandierende TAVI-Klappen bei kleinem Aortenanulus im Vorteil
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise